Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. The Ibutilide/Sotalol Comparator Study Group. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. 29(2):385-90.Ībi-Mansour P, Carberry PA, McCowan RJ, Henthorn RW, Dunn GH, Perry KT. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Comparison of antero-lateral versus antero-posterior electrode position for biphasic external cardioversion of atrial flutter. Risius T, Mortensen K, Schwemer TF, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Page RL, Joglar JA, Caldwell MA, et al, and the Evidence Review Committee Chair‡. Part 4: Advanced life support: 2015 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Callaway CW, Soar J, Aibiki M, et al, for the Advanced Life Support Chapter Collaborators.
Atrial flutter update#
Part 7: Adult advanced cardiovascular life support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Link MS, Berkow LC, Kudenchuk PJ, et al. Classification of atrial flutter and regular atrial tachycardia according to electrophysiologic mechanism and anatomic bases: a statement from a joint expert group from the Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.
Characteristics and outcomes of concurrently diagnosed new rapid atrial fibrillation or flutter and new reduced ejection fraction. Rodriguez Y, Althouse AD, Adelstein EC, et al. Outcomes for emergency department patients with recent-onset atrial fibrillation and flutter treated in Canadian hospitals. Risk of stroke in patients with atrial flutter. 8(11):1661-6.īiblo LA, Yuan Z, Quan KJ, Mackall JA, Rimm AA. Incidence and predictors of major complications from contemporary catheter ablation to treat cardiac arrhythmias. Atrial flutter and the risk of thromboembolism: a systematic review and meta-analysis. Ghali WA, Wasil BI, Brant R, Exner DV, Cornuz J. Incidence and predictors of atrial flutter in the general population. Variants conferring risk of atrial fibrillation on chromosome 4q25. Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Genetic loci on chromosomes 4q25, 7p31, and 12p12 are associated with onset of lone atrial fibrillation before the age of 40 years. Prediction of cardiovascular disease outcomes and established cardiovascular risk factors by genome-wide association markers. Myotonic dystrophy presenting as atrial flutter in childhood. 2015 ACC/AHA/HRS Guideline for the Management of Supraventricular Tachycardia.2019 ESC/AEPC Guidelines for the Management of Supraventricular Tachycardia.Prevention of Thromboembolic Complications.
0 kommentar(er)
